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Carbon Nanotube Membranes for use in the Transdermal 
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Symptoms
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and Audra L. Stinchcomb1
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of Chemical and Materials Engineering, University of Kentucky, Lexington, KY, U.S.A.
Abstract: Transdermal systems are attractive methods of drug administration specifi cally when treating patients for drug 
addiction. Current systems however are defi cient in therapies that allow variable fl ux values of drug, such as nicotine for 
smoking cessation or complex dosing regimens using clonidine when treating opioid withdrawal symptoms. Through the 
use of functionalized carbon nanotube (CNT) membranes, drug delivery to the skin can be controlled by applying a small 
electrical bias to create a programmable drug delivery system. Clearly, a transdermal patch system that can be tailored to an 
individual’s needs will increase patient compliance as well as provide much more effi cient therapy. The purpose of this paper 
is to discuss the applicability of using carbon nanotube membranes in transdermal systems for treatment of drug abuse.
Keywords: transdermal delivery, variable rate, CNT, nicotine, clonidine
Introduction
Drug abuse, whether alcohol, tobacco, prescription or illicit, continues to burden society, economics, 
medical care systems, and the family dynamic. The World Health Organization (WHO) estimates that 
globally 185 million people are illicit drug users and an astounding 1.3 billion individuals are smokers.1 
Smoking related deaths, estimated at nearly 5 million worldwide, continue to be the leading preventable 
cause of death. Additionally, in the United States alone, $167 billion in annual health-related economic 
loss can be attributed to smoking.2 Although there are roughly only 200,000 deaths reported to be 
directly associated with illicit drug use, the detriment to family and society, and the economic costs 
associated with crime, law enforcement, medical care, and drug treatment and rehabilitation, are 
immense.3,4 While current treatments for cigarette smoking and opioid addiction do aid in successful 
abstinence from the individual’s vice, there is great need and room for improvement. The best of smok-
ing cessation therapies reports a mere 19% success after one year, while only 50% of individuals who 
enter clinics for opioid addiction remain for the duration of the treatment, of which 65% return to using 
within 4 weeks.3,5 Clearly, a therapy that better controls cravings or abates withdrawal symptoms to 
decrease the likelihood of relapse is needed. Carbon nanotube (CNT) membranes present the opportu-
nity to create a transdermal patch that can vary its rate of delivery throughout its application to the skin 
to attain therapeutic plasma levels and plasma profi les of a specifi c drug. The purpose of this report is 
to discuss the use of carbon nanotube membranes in a transdermal system to aid in abstinence from 
cigarettes and withdrawal from opioids.
Nicotine and Clonidine as Therapies
Conventional nicotine replacement therapy (NRT) has been on the market since the early 1990s. 
Continuous research and development of the therapy has expanded the delivery from early reservoir 
transdermal patches to matrix systems, gums, inhalers, lozenges, and nasal sprays.6 As the name implies, 
NRT works to replace nicotine, the agent in cigarettes responsible for dependence, with a pure phar-
maceutical source, thereby eliminating the toxic chemicals found in tobacco smoke from entering the 
body. Furthermore, NRT prevents withdrawal symptoms which induce the desire to smoke, thereby 
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increasing a smoker’s ability to put up with the 
environmental and social cues associated with 
smoking. Though current NRTs do aid in smoking 
cessation when compared to individuals who try 
to quit using non-pharmacological treatment or are 
given placebos, the success rate is still an unsatis-
factory 17%.3 A representative daily nicotine 
plasma profi le of a heavy smoker can be seen in 
Figure 1a. It consists of a series of peaks and 
troughs spurred by the smoking of each cigarette 
with rapid, less than fi ve minutes, attainment of 
the maximum nicotine level. Slight accumulation 
can be seen over the course of the day, but the high 
spike of nicotine is always obtained with the 
smoking of a new cigarette.7 NRT’s low success 
rate is primarily due to the fact that no current 
system can actually mimic the rapid attainment of 
high nicotine plasma levels associated with smok-
ing a cigarette.3,8 Nasal spray offers the fastest time 
of delivery to its maximum concentration, but does 
not reach the level required to suppress a nicotine 
craving of a smoker, and like the gum, lozenge or 
inhaler it requires multiple doses throughout the 
day which often leads to issues with patient 
compliance. The current transdermal patch is a 
once daily application, however it cannot safely 
deliver the craving sustaining dose, nor can the 
system deliver it in a rapid manner, mimicking 
the smoking plasma profi le.6 Clearly, a delivery 
system that can rapidly and safely deliver nicotine 
at a level equal to that of a cigarette, followed 
by a return to baseline levels, and then later be 
reactivated when a craving occurs, would be ben-
efi cial to someone attempting to abstain from 
smoking. Furthermore, a system that can be 
tailored to an individual’s smoking schedule would 
provide a more effi cacious treatment than a stan-
dard “one size fi ts all” therapy.
Similarly, a multiple rate delivery system would 
be benefi cial to patients and medical staff when 
treating opiate withdrawal symptoms using cloni-
dine. Currently, clonidine is used in rehabilitation 
clinics to mitigate the symptoms of opiate with-
drawal including rhinorrhea, lacrimation, perspira-
tion, piloerection, gastrointestinal complaints, 
nausea, yawning, sneezing, muscle pain, tachycardia 
and hypertension.4 Clonidine is a partial pre- and 
postsynaptic alpha-adrenoreceptor agonist that 
produces a reduction in peripheral sympathetic 
outflow. Patients experience acute withdrawal 
symptoms between 6 to 12 hours after opioid 
abstinence with peak effects being felt between 
36 to 72 hours and gradual abatement over 5 to 
10 days.3,9 For this reason patients are typically 
given multiple oral clonidine doses, or in a few 
cases a combination of transdermal and oral drug, 
per day during treatment.4,5 A typical fi ve day oral 
treatment profi le can be seen in Figure 1b. Clearly, 
repetitive dosing with variable amounts each day 
puts a strain on the patient and clinical staff. 
Patients who are experiencing withdrawal are 
likely irritable and unreceptive to medical staff 
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Figure 1a. Representative nicotine plasma profi le of a cigarette smoker. Asterisks indicate the smoking of a cigarette.
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who must administer the multiple doses of a drug 
per day. Additionally, patients who suffer nausea 
and gastrointestinal problems during withdrawal 
experience diffi culties in maintaining proper doses 
due to vomiting. A transdermal system that can 
manipulate its delivery rate to provide the required 
dose on specifi c days during a typical clinic stay 
would not only eliminate the physiological dosing 
issues, but also ease the burden of administering, 
monitoring, and tailoring a drug regimen to each 
individual patient.
Transdermal patches tend to be one of the most 
desired therapies by patients and health care pro-
viders, not only for easy and pain-free administra-
tion, but also for several pharmacokinetic and 
pharmacodynamic benefi ts.10,11 Traditional trans-
dermal delivery allows one time application to 
constantly administer drug over a given time, 
thereby eliminating the hassle and diffi culties 
associated with oral or intravenous maintenance 
multiple dosing. This “worry free” administration 
increases patient compliance, which is essential 
when trying to combat drug addiction. Addition-
ally, once a drug passes through the upper echelons 
of the skin, it is directly taken into systemic circu-
lation by the highly vascularized dermal layers. 
This affords the opportunity to lower the amount 
of drug required at the administration site, because 
of the avoidance of fi rst pass metabolism. Not only 
is this more cost effective, but also safer for the 
patient as high levels of compounds can increase 
the chance for toxicity. Furthermore, as mentioned 
previously, gastrointestinal complications can lead 
to diffi cult and improper oral dosing when treating 
patients experiencing opioid withdrawal symptoms. 
Such symptoms would not hamper therapeutic 
regimen designs when delivering the desired phar-
maceutical agent transdermally. Despite the attrac-
tiveness of the transdermal route, one major 
shortcoming exists in effi caciously treating smok-
ing and opioid addiction with currently available 
patches; none of the current marketable transder-
mal patches can deliver the required variable 
dosing rate of drug to effectively treat these addic-
tions in a single, self-contained system. The use of 
CNT membranes in a transdermal system offers a 
feasible solution to this variable rate drug delivery 
predicament.
Carbon Nanotube Membranes
The demand for development of highly functional-
ized chemical screening, separating, purifying and 
delivery devices has risen in the past several 
decades as vast advances in the areas of biology, 
chemistry, electronics and medicine continue to be 
made.12 Nanoporous membranes consisting of 
aligned, multi-walled CNTs in a polymer substrate, 
possessing distinctive properties have demon-
strated their applicability in the areas of electronic 
devices, chemical separation, biosensors, salt water 
desalination and purifi cation, and most recently, in 
the area of drug delivery. More specifi cally, three 
signifi cant properties unique to CNT membranes 
that can be utilized to conquer the diffi culties of a 
variable rate drug therapy are 1) extremely fast 
fl uid fl ow due to graphite planes and large van der 
Waals distance,13 2) well defi ned geometry of 
Figure 1b. Representative 5 day opioid withdrawal symptom treatment with clonidine dosing scheme. On day one two 0.1 mg doses are 
given for a total of 0.2 mg of clonidine, on day two three doses are given and so on.
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ligands at pore entrance resulting from membrane 
synthesis,14 and 3) the concentration of an electric 
fi eld at the tips of CNTs due to their electrically 
conductive properties while surrounded by an 
insulating polymer support.15 Synthesis of these 
membranes has been described previously,16 but 
briefly carbon nanotube arrays are grown by 
chemical vapor deposition (CVD) on a quartz 
substrate using specifi c metal catalysts to control 
the diameter of nanotubes. The spaces between the 
individual tubes are then embedded with a polymer 
substrate and the quartz support etched off using 
hydrofl uoric acid. H2O plasma oxidation is utilized 
to remove excess polymer on the surface of the 
fi lm as well as the initial growth catalyst particle. 
This process results in a robust membrane with 
open-ended CNTs possessing carboxylic function-
ality at the tips. These tips can be further function-
alized with various molecules using carbodiimide 
chemistry to create charged molecular chains that, 
with proper electrical infl uence, will work as a gate 
to chemical transport through the nanotubes.15 
More specifi cally and as seen in Figure 2, by apply-
ing a small electrical bias (50 mV) to the mem-
brane, the end groups, which are negatively 
charged, are either attracted to the nanotubes them-
selves causing blockage of the pore and thus no 
transport, or repelled from one another and sur-
rounding nanotubes causing the functional group 
to stand on end allowing fl uid passage and drug 
delivery through the pore. By incorporating this 
voltage gated membrane into a transdermal system 
(Fig. 3a), programmable controlled dosing either 
by physician or patient is attainable.
Recall that the major set back in current NRT 
therapies is the inability to mimic the actual pul-
satile nicotine delivery profi le and resultant peak 
plasma levels of a smoker. With the ability of a 
patch to deliver a high dose of nicotine and then 
safely shut off to return to baseline plasma levels 
throughout the day, a smoker would be able to 
satisfy their nicotine craving and thereby increase 
their chances of becoming smoking independent. 
Furthermore, these patches can be patient con-
trolled through a push activated button pressed 
at the initiation of a patient’s craving, which 
would apply the electrical bias to the membrane 
allowing drug fl ow to the skin, eliminating patient 
to patient tailoring issues seen with conventional 
therapies. As with all drug addiction and subse-
quent pharmacological replacement treatment, 
the patient must be motivated to quit to truly gain 
independence from whatever drug one is depen-
dent upon.
Similarly, the multiple and variable dosages 
that are utilized to properly treat opioid withdrawal 
symptoms can be simplifi ed to a one time applica-
tion and computer chip controlled transdermal fl ux 
change system. Using multiple membranes within 
the patch will allow for a therapy that is patient 
Figure 2a. No or limited drug diffusion (depending on the size of the attached dendrimer) occurs when a positive bias is applied to the 
membrane. Each nanotube has multiple dendrimers attached to opening as shown in the inset, for simplifi cation purposes only one is shown 
in the larger fi gures.
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tailorable and highly desirable for both patient and 
medical staff. Using the setup seen in 3b, the 
typical clonidine dosing profi le previously dis-
cussed can be achieved by activating one side of 
the patch the fi rst and fourth day, activating both 
membranes the second and third day for the 
highest transdermal fl ux, and by activating only 
the second membrane the fi fth day to taper down 
the dose.
As alluded to earlier, abusers going through 
withdrawal may experience increased sweating, 
variable circulation and based on the degree of 
withdrawal, craving, or intoxication may be quite 
different from patient to patient.17 This variability 
in skin conductance could introduce problems in 
traditional transdermal delivery; however one of 
the main advantages of the CNT membrane system 
is its increased dosing fl exibility. More specifi cally, 
the system cannot only be tailored to an individual 
patient’s needs, but also possesses the added ben-
efi t of fl exibility in drug delivery as conditions 
change over the course of treatment. Because of 
the high doses of nicotine required to effectively 
treat smoking addiction with this nanotube system 
Figure 2b. Drug passes through the nanotubes when a negative bias is applied. The dendrimers remain upright opening the tube because 
of the surrounding negative charges as shown by the arrows.
Patch Cover
Drug Solution
CNT Membrane
Contact Polymer/Adhesive
Figure 3a. Schematic of patch layering using one CNT membrane to produce two different transdermal fl uxes.
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and the fact that the system will be patient activated, 
the potential for lethal overdose is a possibility 
without a proper design. For this reason the patch 
will require a multi-use lockout system; the fi rst 
facet to automatically shut off the patch when the 
proper nicotine amount is delivered, the second to 
prevent the addicted individual from activating the 
patch too often and delivering too much nicotine in 
a short time period. The proper amount of nicotine 
refers to the required amount of drug to be delivered 
transdermally that corresponds to the nicotine 
plasma levels seen immediately following the smok-
ing of a cigarette.Additionally, as discussed, this 
patch setup will involve the use of a small electric 
current to deliver the drug. Currently marketed 
transdermal iontophoresis systems also use electric 
current to deliver drug. However, unlike iontopho-
resis, the electrodes used to deliver the bias are never 
in contact with the skin, nor is the voltage required 
as high; 50 mV for the CNT system compared to 
10 V for iontophoresis.15,18 For these reasons the 
skin irritation and lesions that are often seen with 
the iontophoretic set up are not expected when using 
CNT membranes in a transdermal patch.19
The use of CNT membranes in transdermal 
therapy is fairly cost effective as the membranes 
themselves can be fashioned for as little as 
$0.60/m2. The bulk of the cost of this transdermal 
set up will come from cost of drug and the bias 
control system. The cost of drug will obviously be 
comparable to that of current nicotine and clonidine 
transdermal therapies. The voltage required to 
activate and deactivate the system is no more than 
that which can be supplied by a watch battery, and 
the mechanics of the system, electrodes to provide 
the bias, is comparable to that of the new patient 
activated iontophoteric fentanyl delivery system 
marketed as IONSYSTM.20 Additionally, the volt-
age system would be able to be reused, making the 
drug the only continuous expense throughout the 
therapy.
Therapeutic Feasibility
Despite the simplicity of the system, it was still 
essential to demonstrate that the skin alone could 
permit the required maximum transdermal fl ux, 
proper rate changes, and especially in the case of 
nicotine delivery, do so with minimal lag time. 
A series of proof-of-concept in vitro diffusion stud-
ies were conducted on excised human abdominal 
skin in order to determine if the three parameters 
discussed were feasible for each drug. The average 
smoker has a steady-state nicotine plasma concen-
tration of about 10–20 ng/ml with peak levels 
reaching approximately 54 ng/ml throughout the 
day with each cigarette.7 Using equation 1 in which 
J is the steady-state transdermal fl ux, Css is the 
steady-state plasma concentration, Cl is the total 
body clearance of nicotine, and A is the diffusional 
area (7 cm2), these plasma levels translate to a 
required transdermal fl ux of 0.8 μmol/cm2/h and 
4 μmol/cm2/h for steady-state and peak nicotine 
concentrations, respectively. For a traditional 
Contact Polymer/Adhesive
Patch Cover
CNT1 CNT2
Drug Solution
No
n-C
ond
uct
ive
 Ba
rrie
r
Figure 3b. Schematic of patch layering using two CNT membranes to produce three different transdermal fl uxes.
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fi ve-day opioid withdrawal symptom treatment 
regimen using clonidine, the fi rst and fourth days 
require a total of 0.2 mg per day of oral clonidine, 
days two and three a total of 0.3 mg per day, and 
the fi fth day 0.1 mg of oral clonidine as seen in 
Figure 1b.5 Using a patch size of 10 cm2, 100% 
bioavailability,21 and each day’s oral dose over a 
24 hour period, effective transdermal fl uxes of 
3.5 nmol/cm2/h, 5.4 nmol/cm2/h, and 1.7 nmol/cm2/h 
can be estimated.
 
J
C Cl
A
ss
=
 
(1)
Human skin from abdominoplasty surgery was 
obtained from the National Cancer Institute’s 
Cooperative Human Tissue Network (CHTN). The 
samples were dermatomed immediately upon 
arrival to a thickness of approximately 200 μm and 
frozen at −20 °C. On the day of the experiment, 
the skin was thawed and immediately used for the 
diffusion studies. The abdominal skin was loaded 
into a cell of a PermeGear® In-Line Diffusion 
apparatus (Bethlehem, PA, U.S.A) and charged 
with 250 μl of desired drug solution, and tempera-
ture was maintained at 35 °C (skin surface tem-
perature) by a circulating water bath.22 Solutions 
of 0.9% saline for nicotine and 0.9% saline with 
10% ethanol for clonidine were prepared for use 
as the receiver solutions for diffusion. Multiple 
donor concentrations were used in order to simu-
late a CNT change in drug supply to the skin sur-
face to determine whether a fl ux change would be 
observed through the skin, and to see its associated 
transition (lag) time for rate change. For example, 
after it was determined that a nicotine donor con-
centration of 500 mg/ml would produce the desired 
4 μmol/cm2/h fl ux, this donor solution was applied 
to the skin and the receiver solution was sampled 
over 30 minutes. Next, the donor solution was 
removed and the skin and diffusion cell donor 
chamber quickly rinsed with water to remove any 
residual nicotine on the surface, and a much lower 
donor solution concentration of 50 mg/ml was used 
in order to observe a fl ux change and lag time to 
fl ux change. After another 30 minutes of receiver 
solution sampling, the skin and cell chamber were 
washed again and a donor solution of 500 mg/ml 
was reapplied to the skin, and the receiver solution 
sampled again. This process mimics the activation 
of the carbon nanotube membrane to allow more 
drug fl ow, followed by deactivation and then reac-
tivation, much like a person smoking two cigarettes 
over an hour and a half period. Transition times 
were observed and results can be seen in Table 1. 
The term transition time for this work refers to the 
time it takes between a change in drug rate supply 
to reach the new desired steady-state concentration 
in the receiver solution.
It was also important to investigate the rate of 
drug delivery out of the skin after a donor concen-
tration was removed, in other words the depletion 
of nicotine from the skin after the patch is turned 
off. The residual drug amount that is in the skin 
after the patch is shut off or removed will enter 
systemic circulation and must be taken into con-
sideration when determining the proper time to 
allot between patient initiated activation. For this 
study, varying donor solution concentrations (200, 
300, 400, 500 mg/ml) were applied to the skin 
long enough to reach steady state, and then 
removed and the cell chamber and skin briefl y 
washed with water. Sampling of the receiver solu-
tion was continued for approximately two hours 
with no donor solution on the skin in order to 
observe nicotine depletion. These studies resulted 
Table 1. Therapeutic transdermal fl uxes and transition times for nicotine and clonidine (n = 4).
 Concentration 
(mg/ml)
Transdermal fl ux
(μmol/cm2/h)
Transition 
time (min)
Nicotine 500 4.27 ± 0.22 4.7 ± 0.4
50 1.48 ± 0.22 0
500 4.23 ± 0.25 5.5 ± 0.5
Clonidine 0.225 0.0037 ± 0.00100 322 ± 59*
0.325 0.0053 ± 0.00068 N/A
 0.160 0.0021 ± 0.00096 N/A
*Initial lag time for the fi rst dose.
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in the model seen in Equation 2, where the 
variables correspond to Figure 4 and k is the time 
constant which was 0.088 ± 0.0092 min−1 (Graph-
pad Prism®, La Jolla, CA, U.S.A) and indepen-
dent of donor concentration (p  0.05) (one-way 
ANOVA, SigmaStat3.5©, San Jose, CA, U.S.A). 
This indicated that the skin will not have a sig-
nifi cant depot effect once the patch is removed or 
the system is completely shut off and that proper 
lockout periods can be programmed based on this 
equation.
 Y P Y P e
k X Xe
= + − × − −( ) ( )0  (2)
Clonidine also had to be investigated to ensure 
that the proper therapeutic levels of drug could be 
reached when delivered transdermally, in addition 
to if the skin responds to a change in donor con-
centration allowing a subsequent change in trans-
dermal fl ux. A similar process of applying a donor 
solution followed by a brief washing of the skin 
and diffusion cell donor compartment was 
repeated, except that this time each donor solution 
remained on the skin for 24 hours thereby more 
closely representing therapeutic clonidine deliv-
ery. The required therapeutic fl ux values for each 
of the different doses were achieved and can also 
be seen in Table 1, but it should be noted a short 
transition time between doses is not as important 
as it is with nicotine, as tapering doses over the 
5–10 day treatment are currently used in the 
clinical setting.
Future CNT Membrane Application
It is easy to envision the use of the CNT mem-
brane in therapies not discussed here. Its appli-
cability is wide and the ability to change the rate 
of delivery will prove highly benefi cial in many 
therapeutic areas. Any skin permeable drug is 
suitable for CNT membrane delivery as the 
membrane is not rate limiting in the way the skin 
can be based on size of the molecule or lipophilic-
ity of the drug. CNT membranes do not inhibit 
the use of transdermal techniques to increase the 
breadth of drugs available for use in transdermal 
systems such as prodrugs and codrugs, or the use 
of microneedles prior to patch application.23–26 
Using these techniques in conjunction with CNT 
membranes would not only allow a wider range 
of drugs to be delivered, but also provide more 
fl exibility in programmable rates. By increasing 
the permeation through the skin, the range of high 
to low fl ux through the membrane is increased 
allowing fi ner patient to patient tailoring. Addi-
tionally, a multiple drug delivery system could 
be developed in which two drug reservoirs of 
different content and two separate CNT mem-
branes are utilized. This would allow for simul-
taneous delivery of two drugs at varying rates, or 
for transfer between medications without removal 
and application of a new transdermal system. 
Obviously, size and cost of the device would 
increase as the system becomes more advanced, 
however the benefi ts of variable delivery would 
outweigh these disadvantages in some therapeu-
tic applications.
Conclusions
Carbon nanotube membranes present a feasible 
solution to pitfalls in current smoking cessation 
and opioid withdrawal symptom treatments. 
Therapeutic transdermal fl uxes can be achieved 
and the skin responds well to changes in donor 
concentrations indicating that the skin will not be 
a limiting factor when bias is applied to change 
the fl ux from the patch. This novel method to cre-
ate a rate changing drug delivery device will not 
only increase patient compliance because of the 
multiple benefi ts of using the transdermal route, 
but also provide more effective therapy and 
improve the quality of life for many addicted 
individuals.
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